Cancer feature: cnaPANCAN275

ADAMTS4 APOA2 ARHGAP30 ATF6 ATP1A2 ATP1A4 B4GALT3 C1orf110 C1orf111 C1orf192 C1orf204 C1orf226 CASQ1 CCDC19 CD244 CD48 CD84 COPA DCAF8 DCAF8 DDR2 DEDD DUSP12 F11R FCER1G FCGR2A FCGR2B FCGR3A FCGR3B FCRL6 FCRLA FCRLB HSD17B7 HSPA6 IGSF8 IGSF9 ITLN1 ITLN2 KCNJ10 KCNJ9 KLHDC9 LY9 MPZ NCSTN NDUFS2 NHLH1 NIT1 NOS1AP NR1I3 OLFML2B PCP4L1 PEA15 PEX19 PFDN2 PIGM PPOX PVRL4 RP11-190A12.7 RP11-544M22.13 RP11-565P22.6 SDHC SH2D1B SLAMF1 SLAMF6 SLAMF7 SLAMF8 SLAMF9 TAGLN2 TOMM40L TSTD1 UAP1 UFC1 UHMK1 USF1 USP21 VANGL2 VSIG8

Known Driver Genes: SDHC

Copy number alternation: gain

Navitoclax

The Genomics of Drug Sensitivity in Cancer Project is a collaboration between the Cancer Genome Project at the Wellcome Sanger Institute (UK) and the Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center (USA). This work is funded by Wellcome.

Users have a non-exclusive, non-transferable right to use data files for internal proprietary research and educational purposes, including target, biomarker and drug discovery. Excluded from this licence are use of the data (in whole or any significant part) for resale either alone or in combination with additional data/product offerings, or for provision of commercial services.
Please note: The data files are experimental and academic in nature and are not licensed or certified by any regulatory body. Genome Research Limited provides access to data files on an “as is” basis and excludes all warranties of any kind (express or implied).

Genomics of Drug Sensitivity in Cancer